Eli Lilly's orforglipron could have a few advantages over a pill from Novo Nordisk, including a lack of dietary restrictions ...

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

A closer look at today's Trending Tickers - the stocks making the biggest moves worldwide - including Eli Lilly (LLY), Novo ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

Cash-paying type 2 diabetes patients in the United States can now access Novo Nordisk's Ozempic for $499 per month through ...

Lilly, too, saw revenue take off, quickly joining Novo Nordisk to reign in this high-growth market. Goldman Sachs analysts expect the market for weight loss drugs to hit $130 billion by the end of ...

The two pharma giants are competing intensely. While Novo Nordisk currently holds a commanding lead in the glucagon-like peptide 1 (GLP-1) market, Lilly may have just outmaneuvered its rival.